The Pennant Group Acquires Texas Home Health Provider

The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice, home care and senior living companies, today announced that it has acquired the assets of Cardiovascular Home Care, which provides home health services in Fort Worth, Texas.

The acquisition was effective May 1, 2021 and will operate under the name Custom Care Home Health.

“Having a strong hospice agency and a number of senior living communities in Dallas, we have carefully looked for the right opportunity to add home health services in the DFW area. This acquisition provides a strong platform for our local leaders to better address the needs of the community,” said Danny Walker, Pennant’s Chief Executive Officer. “Throughout our home health and hospice portfolio, there are dozens of opportunities like this to expand our services and be a solution for patients throughout the care continuum,” he added.

“This agency was founded by talented clinicians who believed in providing the highest standard of patient care,” commented Brent Guerisoli, President of Pennant. Noting that the agency admitted approximately 1,500 patients last year, Mr. Guerisoli added, “Their commitment to clinical excellence is demonstrated by their high quality ratings and strong market reputation. We are thrilled to welcome their talented team and look forward to continuing their tradition of outstanding patient care.”

Mr. Guerisoli reaffirmed that Pennant continues to pursue opportunities to acquire home health, hospice, home care and senior living businesses throughout the United States.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.